Skip to main content
. 2016 Feb 26;7(13):16517–16528. doi: 10.18632/oncotarget.7760

Figure 2. Carfilzomib and CUDC-101 synergistically inhibit cellular proliferation in multiple ATC cell lines.

Figure 2

Figure 2

A. Five different ATC cell lines were tested. Each cell line was treated with five different concentrations of carfilzomib, five different concentrations of CUDC-101, and 25 different combinations of carfilzomib and CUDC-101 at various concentrations, as indicated. Cell proliferation levels were determined after 48-h treatments. The numbers of the vehicle control-treated cells were set as the 100% levels. B. Western blot analysis of ubiquitinated proteins after 24h of exposure to carfilzomib treatment (6 and 10 nM for 8505c and 6 nM for C-643), CUDC-101 (0.8 nM for 8505c and 1.2 nM for C-643) or the combination of carfilzomib and CUC-101.